Traditional Chinese medicine wet tissue for relieving rhinitis symptoms of children and application of traditional Chinese medicine wet tissue

Abstract

The invention relates to a traditional Chinese medicine wet tissue for relieving rhinitis symptoms of children, which comprises a wet tissue body and liquid medicine, the wet tissue body is made of non-woven fabric and contains the liquid medicine, and the liquid medicine comprises traditional Chinese medicine liquid and additives, the traditional Chinese medicine liquid is prepared from the following raw materials in parts by weight: 4-8 parts of mint, 4-8 parts of magnolia flower, 4-8 parts of cocklebur fruit, 4-8 parts of agastache rugosus, 1-5 parts of asarum, 7-11 parts of divaricate saposhnikovia root, 10-14 parts of dark plum, 10-14 parts of astragalus membranaceus, 4-8 parts of roasted rhizoma atractylodis macrocephalae, 1-5 parts of ephedra, 1-4 parts of chalcanthite and 1-5 parts of cicada slough. Combined with the local treatment effect of traditional Chinese medicine, the invention embodies the characteristic of external treatment of internal illness in traditional Chinese medicine. The traditional Chinese medicine composition not only has a local nasal cavity cleaning effect and a moistening effect, but also has a treatment effect, and fills the blank of daily maintenance of rhinitis. The selected formula gives consideration to both cold and heat, tonification and purgation, treats both symptoms and root causes, and can relieve rhinitis symptoms. And the traditional Chinese medicine wet tissue is convenient to carry in daily life, can be taken at any time, and has higher feasibility from the principles of safety, convenience, effectiveness and economy.

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine wet tissue for alleviating the symptoms of children's rhinitis and an application thereof. Background Art

[0002] Rhinitis is an inflammatory disease of the nasal mucosa caused by pathogens, allergens and certain systemic diseases. The main symptoms caused by rhinitis include nasal congestion, runny nose, nasal itching, sneezing, etc., which affect the patient's quality of life. In recent years, the age of onset of rhinitis has tended to be younger, and the prevalence has been increasing. Rhinitis has gradually become one of the most common respiratory diseases in children. At present, children's rhinitis is mainly treated with drugs, including antibacterial, anti-allergic, local anti-inflammatory, depletion, and secretion promotion. Traditional Chinese medicine treatment focuses on dispelling wind and phlegm, opening the orifices, and regulating the lung and spleen functions, including Chinese medicine, acupuncture, massage and other treatment methods.

[0003] Chinese patent document CN104857406A discloses a Chinese medicine for treating rhinitis in children. The Chinese medicine for treating rhinitis in children is made of the following raw materials: hawthorn, dried orange peel, angelica dahurica, honeysuckle, asarum, xanthium sibiricum, isatis root, siler, codonopsis pilosula, madder, patrinia, bupleurum, scutellaria baicalensis, goose grass, platycodon, oxyphylla, centipede orchid, eggplant, water morning glory, smilax china, liquorice. The medicinal materials used in the present invention complement each other, according to the Chinese medicine theory prescription, according to a certain weight ratio, it is formulated to have a significant effect on treating rhinitis in children, and it is safe and reliable, and pays more attention to the conditioning of children's body on the basis of treatment of rhinitis in children, reduces the number of onsets and reduces the probability of onset, and has the characteristics of low cost, simple preparation, and significant effect.

[0004] Chinese patent document CN108295167A discloses a Chinese medicine composition, preparation and application for treating rhinitis and sinusitis in children, wherein the Chinese medicine composition comprises 5-15 parts of chrysanthemum, 3-15 parts of scutellaria, 1-10 parts of bupleurum, 1-10 parts of white peony root, 3-15 parts of ginger pinellia, 1-10 parts of cassia twig, and 3-15 parts of magnolia flower by weight. The Chinese medicine composition is based on many years of clinical treatment experience, with chrysanthemum as the monarch, intended to dispel exterior and interior heat evil, clear and descend liver and gallbladder; scutellaria as the minister, intended to clear heat and detoxify, dry dampness and purge fire; bupleurum, white peony root, pinellia, cassia twig as the assistant; magnolia flower as the messenger, which can lead medicine such as lung and stomach, promote lung qi, open the orifices and relieve exterior symptoms, and the combination of these medicines can clear heat and detoxify, soothe the liver and promote lung qi, clear and descend phlegm fire and stomach heat, and can effectively treat rhinitis and sinusitis. The medicinal materials used are mild, do not hurt the vital energy, do not damage the delicate organs, have simple ingredients, are safe and effective, and are not prone to recurrence. They are especially suitable for children's rhinitis and sinusitis, and have important clinical significance and good application prospects.

[0005] There are many traditional Chinese medicine compositions for treating children's rhinitis, but they all have more or less disadvantages, such as too many medicinal flavors, difficult to obtain materials, expensive prices, unclear efficacy, poor therapeutic effect, etc. Therefore, there is an urgent need for a traditional Chinese medicine wet wipe that has obvious effects, few medicinal flavors, is practical, has high compliance, and is safe and effective for relieving the symptoms of children's rhinitis. Summary of the invention

[0006] The purpose of the present invention is to provide a Chinese medicine wet tissue and application thereof for alleviating the symptoms of children's rhinitis in view of the deficiencies in the prior art.

[0007] In the first aspect, the present invention provides a Chinese medicine wet wipe for relieving the symptoms of rhinitis in children, comprising a wet wipe body and a medicinal solution, wherein the wet wipe body is made of non-woven fabric and contains the medicinal solution, wherein the medicinal solution comprises a Chinese medicine solution and an additive, and the Chinese medicine solution is made of the following raw materials in parts by weight: 4-8 parts of mint, 4-8 parts of magnolia flower, 4-8 parts of Xanthium sibiricum, 4-8 parts of Patchouli, 1-5 parts of asarum, 7-11 parts of siler, 10-14 parts of ebony, 10-14 parts of astragalus, 4-8 parts of stir-fried atractylodes, 1-5 parts of ephedra, 1-4 parts of gallstones, and 1-5 parts of cicada shells.

[0008] As a preferred example, the Chinese medicine liquid is made of the following raw materials in parts by weight: 5-7 parts of mint, 5-7 parts of magnolia flower, 5-7 parts of Xanthium sibiricum, 5-7 parts of Patchouli, 2-4 parts of asarum, 8-10 parts of siler, 11-13 parts of ebony, 11-13 parts of astragalus, 5-7 parts of stir-fried atractylodes, 2-4 parts of ephedra, 1-3 parts of gallstones, and 2-4 parts of cicada shells.

[0009] As another preferred example, the Chinese medicine liquid is made of the following raw materials in parts by weight: 6 parts of mint, 6 parts of magnolia flower, 6 parts of Xanthium sibiricum, 6 parts of Patchouli, 3 parts of Asarum, 9 parts of Saposhnikovia divaricata, 12 parts of Prunus mume, 12 parts of Astragalus, 6 parts of stir-fried Atractylodes macrocephala, 3 parts of Ephedra, 2 parts of Gallbladder Vitriol, and 3 parts of Cicadae Periostracum.

[0010] As another preferred example, the additive is at least one of a surfactant, an osmotic pressure regulator, a moisturizer, a transdermal absorption enhancer, a pH regulator, a latent solvent, an antioxidant and an antibacterial agent.

[0011] In a second aspect, the present invention provides the use of Chinese medicinal wet wipes in the preparation of a medicine for relieving the symptoms of rhinitis in children.

[0012] The purpose of the present invention is not only to clean and moisturize the local area, but also to add Chinese herbal ingredients to play a local external treatment role, mainly to dispel wind, resolve phlegm and open the orifices, and relieve rhinitis symptoms. And some children can't or don't want to blow their noses, so the local external wipes can help promote the discharge of secretions.

[0013] The advantages of the present invention are: the present invention combines the local therapeutic effect of traditional Chinese medicine, and embodies the characteristics of traditional Chinese medicine's external treatment of internal diseases. It not only plays a role in local nasal cleaning and moisturizing, but also can play a therapeutic role, filling the gap in daily care of rhinitis. The prescription is selected to take into account both cold and heat, attack and supplement, and treat the symptoms and root causes at the same time, which can relieve the symptoms of rhinitis, shorten the attack period, and prolong the duration of the remission period. It plays an auxiliary role in the prevention and treatment of rhinitis. And the Chinese medicine wet wipes are easy to carry and can be used at any time. From the perspective of safety, convenience, effectiveness, and economy, they are highly feasible. DETAILED DESCRIPTION

[0014] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0015] Example 1 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (I)

[0016] 6 parts of peppermint, 6 parts of magnolia flower, 6 parts of Xanthium sibiricum, 6 parts of Patchouli, 3 parts of asarum, 9 parts of siler, 12 parts of ebony, 12 parts of astragalus, 6 parts of stir-fried atractylodes, 3 parts of ephedra, 2 parts of gallstones, and 3 parts of cicada shells.

[0017] Example 2 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (II)

[0018] 6 parts of peppermint, 5 parts of magnolia flower, 7 parts of Xanthium sibiricum, 4 parts of Patchouli, 5 parts of asarum, 9 parts of siler, 11 parts of ebony, 13 parts of astragalus, 4 parts of stir-fried atractylodes, 5 parts of ephedra, 2 parts of gallstones, and 2 parts of cicada shells.

[0019] Example 3 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (III)

[0020] 5 parts of mint, 7 parts of magnolia flower, 4 parts of xanthium sibiricum, 8 parts of patches, 3 parts of asarum, 8 parts of siler, 13 parts of ebony, 10 parts of astragalus, 8 parts of stir-fried atractylodes, 3 parts of ephedra, 1 part of gallstones, 4 parts of periostracum cicada.

[0021] Example 4 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (IV)

[0022] 7 parts of peppermint, 4 parts of magnolia flower, 8 parts of Xanthium sibiricum, 6 parts of Patchouli, 2 parts of asarum, 10 parts of siler, 10 parts of ebony, 14 parts of astragalus, 6 parts of stir-fried atractylodes, 2 parts of ephedra, 3 parts of gallstones, and 1 part of cicada shell.

[0023] Example 5 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (V)

[0024] 4 parts of peppermint, 8 parts of magnolia flower, 6 parts of Xanthium sibiricum, 5 parts of Patchouli, 4 parts of Asarum, 7 parts of Saposhnikovia divaricata, 14 parts of Prunus mume, 12 parts of Astragalus, 5 parts of stir-fried Atractylodes macrocephala, 4 parts of Ephedra, 1 part of Gallbladder Vitriol, and 5 parts of Periostracum cicadae.

[0025] Example 6 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (VI)

[0026] 8 parts of peppermint, 6 parts of magnolia flower, 5 parts of xanthium sibiricum, 7 parts of patches, 1 part of asarum, 11 parts of siler, 12 parts of ebony, 11 parts of astragalus, 7 parts of stir-fried atractylodes, 1 part of ephedra, 4 parts of gallstones, and 3 parts of periostracum cicada.

[0027] Example 7 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (VII)

[0028] 6 parts of peppermint, 7 parts of magnolia flower, 4 parts of Xanthium sibiricum, 8 parts of Patchouli, 3 parts of Asarum, 8 parts of Saposhnikovia divaricata, 13 parts of Prunus mume, 10 parts of Astragalus, 8 parts of stir-fried Atractylodes macrocephala, 3 parts of Ephedra, 1 part of Gallbladder Vitriol, and 4 parts of Periostracum cicadae.

[0029] Example 8 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (VIII)

[0030] 5 parts of mint, 4 parts of magnolia flower, 8 parts of xanthium sibiricum, 6 parts of patches, 2 parts of asarum, 10 parts of siler, 10 parts of ebony, 14 parts of astragalus, 6 parts of stir-fried atractylodes, 2 parts of ephedra, 3 parts of gallstones, and 1 part of cicada shell.

[0031] Example 9 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (IX)

[0032] 7 parts of peppermint, 8 parts of magnolia flower, 6 parts of Xanthium sibiricum, 5 parts of Patchouli, 4 parts of Asarum, 7 parts of Saposhnikovia divaricata, 14 parts of Prunus mume, 12 parts of Astragalus, 5 parts of stir-fried Atractylodes macrocephala, 4 parts of Ephedra, 1 part of Gallbladder Vitriol, and 5 parts of Periostracum cicadae.

[0033] Example 10 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (ten)

[0034] 4 parts of peppermint, 5 parts of Flos Magnoliae, 5 parts of Fructus Xanthium, 7 parts of Patchouli, 1 part of Asarum, 11 parts of Saposhnikoviae, 12 parts of Prunus Mume, 11 parts of Radix Astragali, 7 parts of stir-fried Atractylodes macrocephala, 1 part of Ephedra, 4 parts of Gallbladder Vitriol, and 3 parts of Periostracum Cicadae.

[0035] Example 11 Chinese medicine liquid in Chinese medicine wet wipes for alleviating symptoms of rhinitis in children (XI)

[0036] 8 parts of peppermint, 5 parts of magnolia flower, 7 parts of Xanthium sibiricum, 4 parts of Patchouli, 5 parts of asarum, 9 parts of siler, 11 parts of ebony, 13 parts of astragalus, 4 parts of stir-fried atractylodes, 5 parts of ephedra, 2 parts of gallstones, and 2 parts of cicada shells.

[0037] Example 12 Preparation method of Chinese medicine wet wipes for alleviating rhinitis symptoms in children

[0038] S1. The Chinese medicine liquid (any one of Embodiment 1 to Embodiment 11) is weighed according to a weight ratio, crushed or ground, concentrated or diluted after extraction, and an additive is added to obtain a medicinal liquid. The extraction includes supercritical extraction, steam distillation extraction, reflux extraction or decoction extraction, and the extraction water is distilled water, purified water, sterile water or deionized water.

[0039] S2. Immersing the non-woven fabric in the above-mentioned medicinal solution, drying, sterilizing, cutting, folding, bagging and sealing to obtain the wet tissue for relieving the symptoms of rhinitis in children.

[0040] Embodiment 13

[0041] 1 Clinical Data

[0042] 1.1 Case source

[0043] The cases observed in this study were all from 100 children with allergic rhinitis who visited the pediatric outpatient clinic of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine between September 2023 and September 2024.

[0044] 1.2 Diagnostic criteria

[0045] Referring to the "Diagnosis and Treatment of Allergic Rhinitis in Children - Clinical Practice Guidelines" published by the "Chinese Journal of Practical Pediatrics" in 2019, the diagnostic criteria for allergic rhinitis in children should be formulated based on the family history and typical allergic history of the child, clinical manifestations, and consistent laboratory test results: (1) Symptoms: 2 or more episodes of nasal itching, sneezing, clear watery discharge, and nasal congestion, with symptoms lasting or accumulating for more than 1 hour per day, and may be accompanied by other concomitant disease symptoms such as respiratory symptoms (coughing, wheezing, etc.) and eye symptoms (including itchy eyes, tearing, red eyes, and burning sensation, etc.). (2) Signs: Common nasal mucosal paleness and edema, and watery nasal secretions. (3) Laboratory tests: Allergen tests for at least 1 allergen SPT and (or) serum specific IgE are positive; nasal secretion tests under a high-power microscope are positive for eosinophil ratios >0.05. The diagnosis of allergic rhinitis in infants and young children can be made based only on allergic history, family history, typical symptoms and signs.

[0046] 1.3 Inclusion criteria

[0047] (1) Meet the above diagnostic criteria, age 0 ～ 14 years old, no gender limitation;

[0048] (2) Those who have the consent of their guardian and signed the informed consent form;

[0049] (3) Ability to cooperate with the planned treatment course.

[0050] 1.4 Exclusion criteria

[0051] (1) Those with congenital nasal deformity or who have undergone nasal surgery;

[0052] (2) Patients with serious diseases of the heart, lung and other systems;

[0053] (3) Those who are allergic to the drugs used in this study;

[0054] (4) Those who have received or intend to receive immunotherapy;

[0055] (5) Participating in other clinical research during the same period.

[0056] 1.5 Rejection and shedding criteria

[0057] (1) Those who fail to receive treatment as planned during the observation period and fail to have follow-up visits at the agreed time, thus seriously affecting the collection of trial data;

[0058] (2) Those who lost contact, were lost to follow-up, dropped out, or actively requested to interrupt treatment during the observation period;

[0059] (3) Serious adverse events occurred during the trial or treatment was discontinued due to worsening of the subject's symptoms.

[0060] 2 Research Methods

[0061] 2.1 Grouping method

[0062] According to the random number table method, the children were divided into a control group of 50 cases and an experimental group of 50 cases. There were 29 males and 21 females in the control group, with an average age of (6.33±2.73) years and an average course of (3.79±2.23) months; there were 31 males and 19 females in the experimental group, with an average age of (6.68±2.63) years and an average course of (3.83±2.16) months. There was no significant difference in the general data of the two groups of children after testing (P>0.05), and they were comparable.

[0063] 2.2 Treatment methods

[0064] The children in the control group received conventional western medicine treatment: fluticasone propionate nasal spray (produced by GlaxoSmithKline, Spain), 1 spray / time in each nostril, 1 time per day, and a daily dose of 100 μg. The children in the experimental group were given the Chinese medicine wet wipes of the present invention on the basis of the above conventional treatment, with the formula: mint 6g, magnolia flower 6g, Xanthium sibiricum 6g, Patchouli 6g, Asarum 3g, Saposhnikovia 9g, Plum 12g, Astragalus 12g, stir-fried Atractylodes 6g, Ephedra 3g, Gallbladder Vitriol 2g, Periostracum Cicadae 3g, rubbing the nose 3 times a day, each time rubbing the nose for 1 minute, and deep breathing was coordinated when rubbing the nose.

[0065] 2.3 Clinical observation indicators

[0066] Symptom quantitative rating form, symptom visual analogue scale (VAS), and rhinoconjunctivitis-related quality of life questionnaire (RQLQ).

[0067] 2.4 Observation time and follow-up methods

[0068] The changes of nasal symptoms and signs in the two groups were observed before treatment, after treatment and 3 weeks after treatment.

[0069] 2.5 Efficacy criteria

[0070] The evaluation was conducted based on the improvement rate of the symptom quantitative score before and after treatment. Improvement rate = [(pre-treatment score - post-treatment score) / pre-treatment score] × 100%. Significantly effective: the improvement rate of the symptom quantitative score after treatment was ≥ 66%. Effective: the improvement rate of the symptom quantitative score after treatment was 26% to 65%. Ineffective: the improvement rate of the symptom quantitative score after treatment was ≤ 25%.

[0071] 2.6 Statistical methods

[0072] All data were statistically analyzed using SPSS 29.0. Normally distributed measurement data were expressed as mean ± standard deviation. Paired t-test was used for intra-group comparison, and one-way analysis of variance was used for inter-group comparison. Rank sum test was used for rank data, and chi-square test was used for unordered categorical data. P < 0.05 indicated statistically significant differences.

[0073] 3 Research results

[0074] 3.1 Comparison of symptom quantitative scores between the two groups before and after treatment

[0075] There was no significant difference in the symptom quantitative scores between the two groups before treatment (P>0.05). There was a significant difference in the symptom quantitative scores between the two groups after treatment compared with those before treatment (P<0.05). The symptom quantitative scores of the experimental group after treatment were lower than those of the control group, and the difference was statistically significant (P<0.05). See Table 1.

[0076] Table 1 Comparison of quantitative symptom scores of the two groups of children before and after treatment (points)

[0077]

[0078] Note: Compared with before treatment, * P<0.05.

[0079] 3.2 Comparison of VAS scores between the two groups before and after treatment

[0080] There was no significant difference in VAS scores between the two groups before treatment (P>0.05). There was a significant difference in VAS scores between the two groups after treatment compared with those before treatment (P<0.05). The VAS score of the experimental group was lower than that of the control group after treatment, and the difference was statistically significant (P<0.05). See Table 2.

[0081] Table 2 Comparison of VAS scores between the two groups of children before and after treatment (points)

[0082]

[0083] Note: Compared with before treatment, * P<0.05.

[0084] 3.3 Comparison of RQLQ scores between the two groups before and after treatment

[0085] There was no significant difference in RQLQ scores between the two groups before treatment (P>0.05). There was a significant difference in RQLQ scores between the two groups after treatment compared with those before treatment (P<0.05). The RQLQ score of the experimental group was lower than that of the control group after treatment, and the difference was statistically significant (P<0.05). See Table 3.

[0086] Table 3 Comparison of RQLQ scores between the two groups of children before and after treatment (points)

[0087]

[0088] Note: Compared with before treatment, * P<0.05.

[0089] 3.4 Comparison of clinical efficacy between the two groups

[0090] The total effective rate of the control group was 80%, and that of the experimental group was 94%. The total effective rate of the experimental group was higher than that of the control group, and the difference was statistically significant (P<0.05). The clinical efficacy of the experimental group was better than that of the control group. See Table 4.

[0091] Table 4 Comparison of clinical efficacy between the two groups of children (%)

[0092]

[0093] 3.5 Comparison of recurrence rates between the two groups 3 weeks after treatment

[0094] The two groups of markedly effective and effective children were followed up 3 weeks after treatment. The results showed that the recurrence rate was 60% in the control group and 38% in the experimental group. The difference in recurrence rate between the two groups was statistically significant (P<0.05). See Table 5.

[0095] Table 5 Comparison of relapse rates between the two groups of children after 3 weeks of treatment (%)

[0096]

[0097] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A Chinese medicine wet wipe for relieving the symptoms of children's rhinitis, comprising a wet wipe body and a medicinal solution, wherein the wet wipe body is made of non-woven fabric and contains the medicinal solution, wherein the medicinal solution comprises a Chinese medicine solution and an additive, and is characterized in that: The traditional Chinese medicine liquid is prepared from the following raw materials in parts by weight: 4-8 parts of mint, 4-8 parts of magnolia flower, 4-8 parts of Xanthium sibiricum fruit, 4-8 parts of Patchouli, 1-5 parts of asarum, 7-11 parts of siler, 10-14 parts of ebony, 10-14 parts of astragalus, 4-8 parts of stir-fried atractylodes, 1-5 parts of ephedra, 1-4 parts of gallstones, and 1-5 parts of cicada shell.

2. The Chinese medicine wet wipe according to claim 1, characterized in that: The traditional Chinese medicine liquid is prepared from the following raw materials in parts by weight: 5-7 parts of mint, 5-7 parts of magnolia flower, 5-7 parts of Xanthium sibiricum fruit, 5-7 parts of Patchouli, 2-4 parts of asarum, 8-10 parts of siler, 11-13 parts of ebony, 11-13 parts of astragalus, 5-7 parts of stir-fried atractylodes, 2-4 parts of ephedra, 1-3 parts of gallstones, and 2-4 parts of cicada shells.

3. The Chinese medicine wet wipe according to claim 1, characterized in that: The Chinese medicine liquid is prepared from the following raw materials in parts by weight: 6 parts of mint, 6 parts of magnolia flower, 6 parts of Xanthium sibiricum fruit, 6 parts of Patchouli, 3 parts of asarum, 9 parts of siler, 12 parts of ebony, 12 parts of astragalus, 6 parts of stir-fried atractylodes, 3 parts of ephedra, 2 parts of gallstones, and 3 parts of cicada shells.

4. The Chinese medicinal wet wipes according to any one of claims 1 to 3, characterized in that: The additive is at least one of a surfactant, an osmotic pressure regulator, a moisturizer, a transdermal absorption enhancer, a pH regulator, a latent solvent, an antioxidant and an antibacterial agent.

5. Use of the Chinese medicinal wet wipes according to any one of claims 1 to 3 in preparing a medicine for relieving symptoms of rhinitis in children.

Images